[
    [
        {
            "time": "2018-11-01",
            "original_text": "UPDATE 1-Novartis nears deal to buy U.S. biotech firm Medicines Co for about $7 bln- WSJ",
            "features": {
                "keywords": [
                    "Novartis",
                    "deal",
                    "buy",
                    "U.S.",
                    "biotech",
                    "Medicines Co",
                    "$7 bln"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-11-01",
            "original_text": "Novartis nears deal to buy U.S. biotech firm Medicines Co for about $7 billion: WSJ",
            "features": {
                "keywords": [
                    "Novartis",
                    "deal",
                    "buy",
                    "U.S.",
                    "biotech",
                    "Medicines Co",
                    "$7 billion"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-11-01",
            "original_text": "Novartis nears $9bn deal to buy cholesterol drugmaker",
            "features": {
                "keywords": [
                    "Novartis",
                    "deal",
                    "buy",
                    "cholesterol",
                    "drugmaker",
                    "$9bn"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]